Posts by Christopher
BioBuzz: Addimmune Prepares to go Public, Initiate Phase Ib HIV Trial
This article highlights the upcoming IPO for Addimmune, the HIV division of American Gene Technologies. This transition aims to secure funds for a crucial Phase 1b clinical trial, which will evaluate the company’s innovative cell therapy for HIV. The therapy leverages genetically modified cells to target the virus directly. Addimmune is encouraged by promising results…
Read MoreMultiple Treatment Interruptions and Protecting HIV-Specific CD4 T-Cells Enables Durable CTL Response and Viral Control
This publication on medRxiv presents exciting data regarding the potential of our gene therapy, AGT-103, in treating HIV. The study examined the effects of strategic ART interruptions in combination with AGT-103 treatment, offering valuable insights into optimizing treatment efficacy. The findings demonstrate that a combined approach involving AGT-103 and strategically timed ART interruptions may lead…
Read MoreAmerican Gene Technologies® to Present at ROTH MKM 2023 Healthcare Opportunities Conference
Rockville, MD, October 11, 2023 — American Gene Technologies® (AGT™), a clinical-stage biotechnology company dedicated to improving human health through innovative gene and cell therapies, today announced that Jeff Galvin, Founder and Chief Executive Officer, will present at the ROTH MKM Healthcare Opportunities Conference held at The Yale Club in New York City, New York,…
Read MorePharmashots: Addimmune to go Public via 10x Capital Venture Acquisition Corp. III SPAC Merger for ~$500M
Addimmune Announces Public Offering via SPAC Merger Addimmune, the HIV division of American Gene Technologies, is making significant strides toward its goal of delivering a gene therapy cure. This article highlights our upcoming merger with 10x Capital Venture Acquisition Corp. III, a special purpose acquisition company (SPAC). This transaction will allow Addimmune to go public,…
Read MoreLawstreet Media: Addimmune Goes Public in Bid to Cure HIV
This article reports on Addimmune’s decision to go public, highlighting the transformative potential of our HIV gene therapy. As the HIV division of American Gene Technologies, we are committed to finding a breakthrough cure for a disease that affects millions globally. Our transition to a publicly traded company positions us for accelerated growth and rapid…
Read MoreAround the Helix: Cell and Gene Therapy Company Updates – August 16, 2023
This article provides an overview of recent news and developments in the fast-paced cell and gene therapy industry. Addimmune, the HIV division of American Gene Technologies, is delighted to be featured alongside other innovative companies pushing the boundaries of treatment for various diseases. The article specifically highlights our ongoing Phase 1 clinical trial for our…
Read MoreBioPharma Dive: HIV cell therapy startup Addimmune heads to Wall Street via blank-check merger
This article reports on Addimmune’s strategic decision to merge with a special purpose acquisition company (SPAC), paving the way for public listing. As the HIV division of American Gene Technologies, we believe this transaction will provide essential resources to accelerate our mission to develop a transformative gene therapy for HIV. The merger with 10X Capital…
Read MoreEnd Points News: HIV cell therapy biotech Addimmune to go public via SPAC merger; WHO names new Covid-19 ‘variant of interest’
Access to the desired content is restricted by a paywall. To proceed to the publisher’s website, kindly follow the provided link. https://endpts.com/hiv-cell-therapy-biotech-addimmune-to-go-public-via-spac-merger-who-names-new-covid-19-variant-of-interest/
Read MoreAddimmune to Go Public Through Business Combination with 10X Capital Venture Acquisition Corp. III
Originally Posted on: Global Newswire NEW YORK CITY, NEW YORK and ROCKVILLE, MARYLAND, Aug. 9, 2023 (GLOBE NEWSWIRE) – American Gene Technologies International Inc. (“AGT”) and 10X Capital Venture Acquisition Corp. III (“10X III”) (NYSE: VCXB), a special purpose acquisition company, today announced that they have entered into a merger agreement for a business combination…
Read More